The present study provides two novel findings: (i) serum LEAP2 concentrations are significantly elevated in patients with insulinoma and correlate with insulin levels, and (ii) LEAP2 peptide is extensively expressed in insulinoma tissues. This evidence concerns the gene INS and pancreatic insulinoma.